Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 once monthly for HIV prevention
NCT06045507Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of mk-8527 in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Merck & Co. Primary endpoints: Adverse Events at 28 weeks and Discontinuation Due to Adverse Events at 20 weeks. Started Nov 2023; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06045507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045507.